CHMP recommends extension of Fintepla indication to include Lennox-Gastaut syndrome
The Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion recommending a change to the terms of the marketing authorisation for the medicinal product Fintepla (fenfluramine (oral)
The marketing authorisation holder for this medicinal product is Zogenix ROI Limited/UCB.
The CHMP adopted a new indication to add treatment of seizures associated with Lennox-Gastaut syndrome. For information, the full indications will therefore be as follows: Fintepla is indicated for the treatment of seizures associated with Dravet syndrome and Lennox-Gastaut syndrome as an add-on therapy to other anti-epileptic medicines for patients 2 years of age and older.
Learning Zones
The Learning Zones are an educational resource for healthcare professionals that provide medical information on the epidemiology, pathophysiology and burden of disease, as well as diagnostic techniques and treatment regimens.
1 mins